Is Quizartinib available in the country and the formal channels for purchasing it?
Quizartinib is an oral, second-generation FLT3 tyrosine kinase inhibitor, mainly used to treat patients with FLT3 mutation-positive acute myeloid leukemia (AML). Although it has been approved and widely used internationally, as of now, Quizartinib has not been officially approved for marketing in China. Therefore, if domestic patients need to use the drug, they can only purchase it through foreign channels for the time being.
Since Quizartinib is not yet available in China, patients should be extremely cautious when seeking ways to purchase the drug. Formal drug purchasing channels mainly include ordering imported drugs through overseas medical institutions or overseas regular pharmacies. At the same time, some patients choose to obtain pharmaceutical support through international medical tourism or cross-border medical services. It should be reminded that patients and their families must avoid purchasing through informal channels to prevent buying fake and shoddy products, which may affect the treatment effect or even endanger their health.
In foreign markets, Quizartinib has two options: original drug and generic drug. The original version is more expensive, while the imitation versions produced in some countries and regions are more affordable. For example, the generic drug Quizartinib produced by Laos Lucius Company has two specifications: 17.7mg 14 tablets and 26.5mg 14 tablets. The price is about more than 1,000 yuan. It is cost-effective and has become the choice of many patients.
To sum up, although Quizartinib has not yet been approved for marketing in China, patients need to obtain the drug through regular overseas channels to ensure the safety and effectiveness of the drug. With the increase in clinical demand and the gradual improvement of policies, it is more likely that Quizartinib will be launched in China in the future. By then, patients will enjoy more convenient drug purchase services and more comprehensive medication protection.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)